Bain Capital Life Sciences Investors’s Dianthus Therapeutics DNTH Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.3M	Hold	362,470	–	–	2.1%	12
2026 Q1	$30.4M	Sell	362,470 -381,122	-51%	-$22.1M	2.74%	8
2025 Q4	$30.6M	Sell	743,592 -572,300	-43%	-$22.2M	2.35%	9
2025 Q3	$51.8M	Sell	1,315,892 -1,166,358	-47%	-$29.8M	3.44%	7
2025 Q2	$46.2M	Sell	2,482,250 -207,457	-8%	-$3.89M	5.79%	5
2025 Q1	$48.8M	Hold	2,689,707	–	–	7.22%	5
2024 Q4	$58.6M	Sell	2,689,707 -323,716	-11%	-$8.32M	6.9%	5
2024 Q3	$82.5M	Hold	3,013,423	–	–	8.58%	4
2024 Q2	$78M	Buy	3,013,423 +21,395	+0.7%	+$514K	8.56%	4
2024 Q1	$89.8M	Buy	+2,992,028	New	+$65M	7.21%	3

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Bain Capital Life Sciences Investors's DNTH Position: Q2 2026 in Review

Bain Capital Life Sciences Investors held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 362,470 shares worth $35.3M. The position accounts for 2.1% of the portfolio, ranked #12.

Bain Capital Life Sciences Investors first reported a position in DNTH in Q1 2024 and has held it in 10 quarters since. The position peaked at $89.8M in Q1 2024. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Bain Capital Life Sciences Investors held 362,470 shares of Dianthus Therapeutics worth $35.3M as of Q2 2026.
Bain Capital Life Sciences Investors left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 2.1% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #12 holding.
Bain Capital Life Sciences Investors first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 10 quarters since.
Bain Capital Life Sciences Investors's Dianthus Therapeutics position peaked at $89.8M in Q1 2024.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.